Greenwich LifeSciences (NASDAQ: GLSI) CEO adds 3,600 shares in open-market buys

Rhea-AI Filing Summary

Greenwich LifeSciences CEO, CFO and 10% owner Snehal Patel purchased a total of 3,600 shares of Common Stock in two reported transactions, buying 2,500 shares at $13.14 per share on July 23, 2026 and 1,100 shares at $12.88 per share on July 24, 2026, all recorded as direct ownership.

Insider Trade Summary

Net Buyer: 3,600 shares

Net Buy 2 txns

Insider Patel Snehal

Role CEO and CFO

Bought 3,600 shs ($47K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,100	$12.88	$14K
Purchase	Common Stock	2,500	$13.14	$33K

Holdings After Transaction: Common Stock — 5,607,702 shares (Direct)

Key Figures

Shares purchased on 2026-07-23: 2500.0000 shares Shares purchased on 2026-07-24: 1100.0000 shares Total shares purchased: 3600 shares

3 metrics

Shares purchased on 2026-07-23 2500.0000 shares Common Stock bought at $13.1400 per share by Snehal Patel

Shares purchased on 2026-07-24 1100.0000 shares Common Stock bought at $12.8800 per share by Snehal Patel

Total shares purchased 3600 shares Aggregate Common Stock purchases reported in this Form 4

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/27/2026 - 06:15 AM Accepted by SEC EDGAR 07/27/2026 - 06:15 AM Learn about SEC filing dates

FAQ

What insider stock purchases did GLSI report for Snehal Patel?

Greenwich LifeSciences reported that CEO, CFO and 10% owner Snehal Patel bought a total of 3,600 GLSI common shares. The purchases occurred in two transactions on July 23 and July 24, 2026, at prices of $13.14 and $12.88 per share.

On what dates did GLSI’s CEO buy additional shares?

GLSI’s CEO Snehal Patel purchased shares on July 23, 2026 and July 24, 2026. These two consecutive-day transactions together totaled 3,600 shares of Greenwich LifeSciences Common Stock, according to the reported Form 4 insider trading data.

How many GLSI shares did Snehal Patel buy in each transaction?

Snehal Patel bought 2,500 shares of GLSI Common Stock in one transaction and 1,100 shares in another. These purchases, totaling 3,600 shares, were reported as direct holdings and classified as non-derivative Common Stock acquisitions.

What prices did GLSI insider Snehal Patel pay for the purchased shares?

Snehal Patel paid $13.14 per share for 2,500 GLSI shares on July 23, 2026 and $12.88 per share for 1,100 shares on July 24, 2026. Both transactions were recorded as purchases of Common Stock.

Were Snehal Patel’s GLSI share purchases under a Rule 10b5-1 trading plan?

These transactions are not marked as executed under a Rule 10b5-1 trading plan. The Form 4-level Rule 10b5-1 affirmation checkbox is set to false, indicating the purchases were not reported as pre-arranged trading plan transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Snehal

(Last) (First) (Middle)

C/O GREENWICH LIFESCIENCES, INC.

3992 BLUEBONNET DR., BUILDING 14

(Street)

STAFFORD TEXAS 77477

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Greenwich LifeSciences, Inc. [ GLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		P		2,500	A	$13.14	5,606,602	D
Common Stock	07/24/2026		P		1,100	A	$12.88	5,607,702	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Snehal Patel	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)